lilly-logo-2--1
Photo: Courtesy of Eli Lilly
1 November 2016Americas

Eli Lilly sues Cipla for infringing testosterone patents

Eli Lilly has filed a complaint against India-based drug company Cipla for allegedly infringing its patents covering Axiron (testosterone topical).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
3 June 2021   Clarus Therapeutics has convinced a US court to invalidate four Lipocine testosterone booster patents it was accused of infringing.

More on this story

Big Pharma
3 June 2021   Clarus Therapeutics has convinced a US court to invalidate four Lipocine testosterone booster patents it was accused of infringing.

More on this story

Big Pharma
3 June 2021   Clarus Therapeutics has convinced a US court to invalidate four Lipocine testosterone booster patents it was accused of infringing.